Mogens Groenvold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mogens Groenvold has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Peter Fayers
Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
2 shared publications A Bottomley
1 shared publicationA Cull
1 shared publicationA de Graeff
1 shared publicationG Collins
1 shared publicationHenning T Mouridsen
Department of Oncology ONK, Finsen Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
1 shared publication
Latest Publications
- 30 September 2001
- Published by Elsevier in Value in Health
- Vol. 4 (6) , 437-438
PCN17: PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS
- 30 September 2001
- Published by Elsevier in Value in Health
- Vol. 4 (6) , 437-438
PCN17: PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS
- 1 June 1999
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 52 (6) , 523-530
Anxiety and Depression in Breast Cancer Patients at Low Risk of Recurrence Compared with the General Population
- 1 June 1999
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 52 (6) , 523-530
Anxiety and Depression in Breast Cancer Patients at Low Risk of Recurrence Compared with the General Population
- 1 August 1998
- Published by Springer Nature in Quality of Life Research
- Vol. 7 (6) , 479-486
Testing for differences in multiple quality of life dimensions: generating hypotheses from the experience of hospital staff
In clinical trials with a quality of life (QoL) component, it is usual to monitor several QoL dimensions at several points in time. Multiple significance tests without formal hypotheses are...
- 1 August 1998
- Published by Springer Nature in Quality of Life Research
- Vol. 7 (6) , 479-486
Testing for differences in multiple quality of life dimensions: generating hypotheses from the experience of hospital staff
In clinical trials with a quality of life (QoL) component, it is usual to monitor several QoL dimensions at several points in time. Multiple significance tests without formal hypotheses are...
- 1 May 1998
- Published by Kluwer Law International BV
- Vol. 7 (4) , 291-300
The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group.
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Study Group has adopted a modular approach to quality of life (QoL) assessment in cancer clinical trials. The core instrument (the EORTC QLQ-C30) covers a range of QoL issues relevant to a broad spectrum of patients with cancer. The QLQ-C30 is designed to be supplemented by more specific subscales ('modules') to assess aspects of QoL of particular importance to specific subgroups of patients. Since individual members of the study group were to be involved in module development, guidelines were established. The primary aim of these guidelines was to standardize the module development process in order to ensure uniformly high quality across modules. This paper gives an update of the work completed to date. First, while the guidelines proved practical for module development, producing modules that exhibit adequate levels of psychometric and cross-cultural validity, experience pointed to three areas where the guidelines required more precision. These amendments will be provided and include (1) stricter monitoring of the developmental process from within the study group, (2) the explicit requirement of involvement of the study group and (3) a more precise definition of the criteria to be fulfilled before modules are allowed to be called 'EORTC modules'. Second, an overview of the modules currently under development or available for general use is provided. These modules include those for body image, high-dose chemotherapy, leukaemia, myeloma, palliative care and the following cancers: bladder, brain, breast, colorectal, head and neck, lung, oesophageal, ophthalmic, ovarian, pancreas and prostate. Finally, the need for the coordination of efforts in module development, both from within and outside the EORTC, is discussed.
- 1 May 1998
- Published by Kluwer Law International BV
- Vol. 7 (4) , 291-300
The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group.
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Study Group has adopted a modular approach to quality of life (QoL) assessment in cancer clinical trials. The core instrument (the EORTC QLQ-C30) covers a range of QoL issues relevant to a broad spectrum of patients with cancer. The QLQ-C30 is designed to be supplemented by more specific subscales ('modules') to assess aspects of QoL of particular importance to specific subgroups of patients. Since individual members of the study group were to be involved in module development, guidelines were established. The primary aim of these guidelines was to standardize the module development process in order to ensure uniformly high quality across modules. This paper gives an update of the work completed to date. First, while the guidelines proved practical for module development, producing modules that exhibit adequate levels of psychometric and cross-cultural validity, experience pointed to three areas where the guidelines required more precision. These amendments will be provided and include (1) stricter monitoring of the developmental process from within the study group, (2) the explicit requirement of involvement of the study group and (3) a more precise definition of the criteria to be fulfilled before modules are allowed to be called 'EORTC modules'. Second, an overview of the modules currently under development or available for general use is provided. These modules include those for body image, high-dose chemotherapy, leukaemia, myeloma, palliative care and the following cancers: bladder, brain, breast, colorectal, head and neck, lung, oesophageal, ophthalmic, ovarian, pancreas and prostate. Finally, the need for the coordination of efforts in module development, both from within and outside the EORTC, is discussed.